B. animalis

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Bifidobacterium animalis—most often specified as B. animalis subsp. lactis—is studied primarily in (1) clinical outcomes in vulnerable neonatal populations, (2) associations between gut microbiota composition and host phenotypes (notably obesity/lean status and age-related colonization patterns), and (3) formulation/synbiotic strategies that improve viability and functional outputs (e.g., microencapsulation, pairing with specific oligosaccharides such as HMOs). Compared with other common bifidobacterial taxa, population-level surveys suggest B. animalis subsp. lactis is not a dominant, broadly distributed resident across the lifespan (detected in a minority of individuals with age-restricted presence in one Japanese cohort), which is consistent with it often being considered a strain used in foods/supplements rather than a ubiquitous core commensal.

The strongest evidence in these abstracts supports efficacy in preterm, low-birth-weight neonates: a network meta-analysis of 63 randomized trials (15,712 infants) found moderate-to-high certainty evidence that probiotic regimens including B. animalis subsp. lactis can reduce severe necrotizing enterocolitis (NEC) versus placebo, and that B. animalis subsp. lactis may reduce length of hospitalization. The same analysis indicates that multi-strain combinations (≥1 Lactobacillus spp plus ≥1 Bifidobacterium spp) have the most consistent evidence for reducing all-cause mortality and severe NEC, suggesting that B. animalis benefits may be context- and formulation-dependent. Outside neonatology, human observational data linking B. animalis to body weight are suggestive but not definitive: one qPCR-based case-control study reported a trend toward association with normal weight (borderline statistical significance), which supports hypothesis generation rather than causal inference.

Key gaps include strain-specificity, mechanisms, and generalizability. Several abstracts emphasize that effects can differ markedly by strain and by synbiotic pairing (e.g., differential growth responses to inulin/FOS/GOS mixtures; enhanced survival and metabolic outputs with HMO/6′-SL plus microencapsulation; shifts in fermentation products and community composition in vitro). However, much of this evidence is in vitro or formulation-focused, and translation to clinically meaningful outcomes in broader populations (e.g., adults with obesity, older adults, bone health/osteoporosis, inflammatory conditions such as severe acute pancreatitis) remains insufficiently established in the provided material. Future research priorities include well-controlled, strain-identified human trials beyond preterm infants; mechanistic studies linking colonization/engraftment, metabolite production (e.g., acetate/SCFAs), and host endpoints; and comparative effectiveness work to disentangle when B. animalis performs best as a single strain versus within multi-strain consortia and specific prebiotic matrices.

1. What conditions has B. animalis been studied for?

  • Body weight/obesity association (observational human data): Stool microbiota profiling in obese vs. normal-weight controls assessed Bifidobacterium animalis abundance and its association with weight status.

  • Preterm, low-birth-weight neonate outcomes (randomized trials summarized in a network meta-analysis): Including severe necrotizing enterocolitis (NEC), all-cause mortality, culture-proven sepsis, time to full feeds, and duration of hospitalization. The meta-analysis specifically identified B. animalis subsp. lactis as an evaluated single-species intervention.

  • Cardiometabolic markers in older overweight adults (randomized controlled trial): Blood pressure and serum lipids using B. animalis subsp. lactis Bb12 combined with Lactobacillus acidophilus La5 (yogurt and/or capsules).

  • Synbiotic/prebiotic utilization and formulation research (in vitro): Growth of B. animalis subsp. lactis with inulin/FOS/GOS and mixed oligosaccharides; microencapsulation to improve survival; human milk oligosaccharide (HMO) 6’-sialyllactose (6’-SL) effects on growth and acetate production; in vitro fecal fermentation effects on SCFAs and microbial composition.

  • Aging/oxidative stress (animal model): A mixed probiotic + postbiotic formula including B. animalis subsp. lactis CP-9 and another B. animalis subspecies strain (listed as “subsp. infantis” BLI-02) evaluated for oxidative stress markers, gut microbiota shifts, and SCFAs in aged mice.

  • Bone health/osteoporosis (mentioned but abstract is incomplete): The provided osteoporosis abstract is truncated, so specific outcomes/strains can’t be extracted from it here.

  • Colonization across the lifespan (cross-sectional observational study): Detection rates of B. animalis subsp. lactis across ages 0–104 years in healthy Japanese subjects.

2. Does it work in treating those conditions? Summarize the evidence.

  • Preterm infant outcomes (NEC, mortality, feeding, hospitalization): The network meta-analysis of 63 trials (15,712 infants) found that compared with placebo, B. animalis subsp. lactis was among interventions with moderate/high-quality evidence for reducing severe NEC (OR 0.31; 95% CI 0.13–0.74). It also reported reduced duration of hospitalization for B. animalis subsp. lactis (mean reduction 13.0 days; 95% CI reduction 22.71–3.29 days). For all-cause mortality, the only intervention with moderate/high-quality evidence was combinations of ≥1 Lactobacillus spp + ≥1 Bifidobacterium spp (OR 0.56; 95% CI 0.39–0.80), rather than B. animalis alone.

    Limitations: This is a synthesis across many formulations and trial designs; effects may be strain-, dose-, and setting-dependent, and the abstract does not provide safety subgroup details (e.g., extremely low birth weight) or strain-by-strain mortality effects.

  • Blood pressure and lipids (older overweight adults): In a 6-week double-blind factorial RCT (n=156) using L. acidophilus La5 + B. animalis subsp. lactis Bb12 (≥3.0×109 CFU/day per probiotic test article), probiotic yogurt compared with control milk did not significantly alter blood pressure (the abstract indicates no significant change; the remainder of the lipid results are truncated in the provided text). Because the intervention combined two species, the independent effect of B. animalis cannot be isolated from this abstract.

    Limitations: Short duration (6 weeks), older overweight population, and combination product; incomplete abstract prevents full lipid interpretation here.

  • Obesity/weight status: In the stool qPCR study (68 obese, 47 controls), B. animalis showed an association with normal weight that was borderline/non-significant (OR 0.63; 95% CI 0.39–1.01; P=0.056). This does not demonstrate treatment efficacy; it suggests a possible relationship between higher detection/abundance and leanness.

    Limitations: Observational association (no causality), single study, and borderline P-value.

  • Aging/oxidative stress (mice): A mixed probiotic + postbiotic formula including B. animalis subsp. lactis CP-9 was associated with improved antioxidative levels in multiple organs and increased serum SCFAs (notably butyrate) in aged mice, especially at higher doses. This supports potential benefit but is not direct evidence of clinical efficacy in humans and cannot be attributed solely to B. animalis.

  • Synbiotics/formulation (in vitro): Multiple oligosaccharides promoted growth of B. animalis subsp. lactis more than single oligosaccharides in vitro; 6’-SL increased growth and acetate yield of a B. animalis strain and increased SCFA production in in vitro fecal fermentation while shifting microbial composition. These are mechanistic/preclinical findings, not proof of clinical treatment benefit.

3. What health benefits does it have?

  • Potential protection in preterm infants (strongest clinical signal in the provided abstracts): In the network meta-analysis, B. animalis subsp. lactis was associated with reduced severe NEC (OR 0.31; 95% CI 0.13–0.74) and shorter hospitalization (mean reduction 13 days; 95% CI reduction 22.71–3.29 days) versus placebo.

  • Possible association with healthier weight status: In one human observational study, B. animalis trended toward association with normal weight (OR 0.63; P=0.056), suggesting it may be a marker (or contributor) to a microbiome profile linked to leanness—though causality is unproven.

  • Supports synbiotic strategies and SCFA production (mechanistic): In vitro, certain prebiotics (including mixed oligosaccharides and 6’-SL) increased growth and acetate production of B. animalis strains and increased SCFAs in fecal fermentation models, with reported reductions in some potentially harmful taxa and enrichment of Akkermansia muciniphila in that model.

  • Potential role in healthy aging/oxidative stress modulation (preclinical): In aged mice, a formula including B. animalis subsp. lactis was associated with improved antioxidative markers and increased SCFAs (notably butyrate), alongside microbiome shifts.

  • Practical benefit: formulation stability/viability: Microencapsulation (including HMO-supplemented microcapsules) improved simulated GI survival and storage stability of a B. animalis strain in vitro, which could improve the likelihood of delivering viable cells to the gut (a prerequisite for many probiotic effects).

4. Does it have any downsides or side effects?

  • Safety outcomes are not detailed in the provided abstracts: The neonatal network meta-analysis reports efficacy outcomes but the abstract does not summarize adverse events. Probiotic safety in preterm infants is an important consideration (e.g., rare probiotic-associated bloodstream infection has been reported in the broader literature), but this cannot be confirmed or quantified from the provided text.

  • Strain- and context-dependence: The obesity association study emphasizes species/strain-specific relationships (some species linked to obesity, others to normal weight). This underscores that benefits cannot be assumed for all strains or all populations.

  • Colonization may be limited/variable: In the lifespan survey, B. animalis subsp. lactis was detected in only 11.4% of healthy subjects and showed atypical correlation patterns versus other bifidobacteria, suggesting it may not be a stable resident in many people (potentially implying effects may require ongoing intake).

  • GI symptoms (not reported here): Common probiotic side effects such as transient gas/bloating are not discussed in these abstracts, so no abstract-based estimate can be provided.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are provided in the supplied abstracts. None report differential response or adverse effects of B. animalis by host genotype (e.g., variants affecting immunity, metabolism, or carbohydrate digestion), nor do they evaluate gene–probiotic interactions. At present, based on these abstracts alone, there is insufficient evidence to say B. animalis is specifically beneficial or harmful for any particular genetic variation.

References

  1. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii.
    M Million, M Maraninchi, M Henry, F Armougom, H Richet, P Carrieri, R Valero, D Raccah, B Vialettes, D Raoult (2012) - International journal of obesity (2005)
  2. Probiotics Reduce Mortality and Morbidity in Preterm, Low-Birth-Weight Infants: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Rebecca L Morgan, Geoffrey A Preidis, Purna C Kashyap, Adam V Weizman, Behnam Sadeghirad (2020) - Gastroenterology
  3. Bifidobacterium improves oestrogen-deficiency-induced osteoporosis in mice by modulating intestinal immunity.
    Jincan Zhang, Xi Liang, Xiaoying Tian, Maozhen Zhao, Yunjuan Mu, Huaxi Yi, Zhe Zhang, Lanwei Zhang (2024) - Food & function
  4. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics.
    Yao Dong, Mei Han, Teng Fei, Huan Liu, Zhonghui Gai (2024) - International microbiology : the official journal of the Spanish Society for Microbiology
  5. Bifidobacterium spp. and their metabolite lactate protect against acute pancreatitis via inhibition of pancreatic and systemic inflammatory responses.
    Han Li, Jinyan Xie, Xiuliu Guo, Guilian Yang, Bin Cai, Jingtianyi Liu, Mengjia Yue, Yixin Tang, Gan Wang, Shuxian Chen, Jialin Guo, Xuchen Qi, Donghai Wang, Huijun Zheng, Wei Liu, Hong Yu, Chunfeng Wang, Shu Jeffrey Zhu, Feng Guo (2022) - Gut microbes
  6. Preparation and synbiotic interaction mechanism of microcapsules of Bifidobacterium animalis F1-7 and human milk oligosaccharides (HMO).
    Xiaoyang Huang, Rui Liu, Jing Wang, Yuexin Bao, Huaxi Yi, Xiaohong Wang, Youyou Lu (2024) - International journal of biological macromolecules
  7. Age-Related Changes in the Composition of Gut Bifidobacterium Species.
    Kumiko Kato, Toshitaka Odamaki, Eri Mitsuyama, Hirosuke Sugahara, Jin-Zhong Xiao, Ro Osawa (2017) - Current microbiology
  8. Probiotics and their Metabolites Reduce Oxidative Stress in Middle-Aged Mice.
    Wen-Yang Lin, Jia-Hung Lin, Yi-Wei Kuo, Pei-Fang Rose Chiang, Hsieh-Hsun Ho (2022) - Current microbiology
  9. Antimicrobial activity and antibiotic susceptibility of
    Ralitsa Georgieva, Lyubomira Yocheva, Lilia Tserovska, Galina Zhelezova, Nina Stefanova, Akseniya Atanasova, Antonia Danguleva, Gergana Ivanova, Nikolay Karapetkov, Nevenka Rumyan, Elena Karaivanova (2015) - Biotechnology, biotechnological equipment
  10. Combination of
    Sing-Chung Li, Wei-Fang Hsu, Jung-Su Chang, Chun-Kuang Shih (2019) - Nutrients
  11. Specific properties of probiotic strains: relevance and benefits for the host.
    Rostyslav V Bubnov, Lidiia P Babenko, Liudmyla M Lazarenko, Victoria V Mokrozub, Mykola Ya Spivak (2018) - The EPMA journal
  12. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial.
    K L Ivey, J M Hodgson, D A Kerr, P L Thompson, B Stojceski, R L Prince (2015) - Nutrition, metabolism, and cardiovascular diseases : NMCD
  13. Bifidobacteria exert species-specific effects on constipation in BALB/c mice.
    Linlin Wang, Lujun Hu, Qi Xu, Tian Jiang, Shuguang Fang, Gang Wang, Jianxin Zhao, Hao Zhang, Wei Chen (2017) - Food & function
  14. Multi-function screening of probiotics to improve oral health and evaluating their efficacy in a rat periodontitis model.
    Qingqing Nie, Xuchun Wan, Hua Tao, Qianqian Yang, Xueyang Zhao, Haixia Liu, Jun Hu, Yanan Luo, Ting Shu, Ran Geng, Zhijing Gu, Fengkai Fan, Zhi Liu (2023) - Frontiers in cellular and infection microbiology
  15. Effect of freeze-dried protectants on the survival rate and fermentation performance of fermented milk's directed vat set starters.
    Yue Tian, Zuyan He, Laping He, Cuiqin Li, Shunbin Qiao, Han Tao, Xiao Wang, Xuefeng Zeng, Yun Tian (2024) - Cryobiology
  16. Cell-Free Culture Supernatant of
    Darshana Kadekar, Andreea Cornelia Udrea, Steffen Yde Bak, Niels Christensen, Kirsty Gibbs, Chong Shen, Marion Bernardeau (2024) - Microorganisms
  17. Genomic and epigenetic landscapes drive CRISPR-based genome editing inBifidobacterium
    Meichen Pan, Wesley Morovic, Claudio Hidalgo-Cantabrana, Avery Roberts, Kimberly K O Walden (2022)
  18. The Probiotic Combination of
    Emili Barba-Vidal, Lorena Castillejos, Victor F B Roll, Gloria Cifuentes-Orjuela, José A Moreno Muñoz, Susana M Martín-Orúe (2017) - Frontiers in microbiology
  19. Effect of a probiotic fermented milk supplementation on behavior and sleep.
    Samara M Freitas, Beatriz Franco, Giulio Saragiotto, Milca A Morais, Fernando M Simabuco, Diogo T Cunha, Andrea M Esteves, Adriane E C Antunes (2024) - Nutritional neuroscience
  20. Effects of phototherapy combined with Lactobacillus salivarius AP-32 or Bifidobacterium animalis subsp. lactis CP-9 on improving neonatal jaundice and gut microbiome health: a randomized double-blind clinical study.
    Ming-Luen Tsai, Shang-Po Shen, Yin-Ting Chen, Hsiao-Yu Chiu, Hsiang-Yu Lin, Hao-Wen Cheng, Yi-Wei Kuo, Jia-Hung Lin, Hui-Shan Wang, Yen-Yu Huang, Ching-Min Li, Yu-Hshun Chin, Hsieh-Hsun Ho, Hung-Chih Lin (2025) - Nutrition journal


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!